Influenza vaccination in heart transplant recipients

J Heart Lung Transplant. 1999 Mar;18(3):220-5. doi: 10.1016/s1053-2498(98)00013-8.

Abstract

Seventy-nine heart transplant recipients were vaccinated with a trivalent influenza virus vaccine 1996/97 containing the strains A/Singapore/6/86 (H1N1), A/Wuhan/395/95 (H3N2), and B/Beijing/184/93. The proportions of patients with protective levels of antibody (HI > or = 40) after vaccination ranged from 100% (A/Singapore [H1N1]) to 31.6% (B/Beijing) and their mean fold titer increases were lower than those recorded for vaccination of 109 healthy subjects with the same batch of vaccine. The vaccinations were tolerated well and did not result in serious side effects, such as graft rejections. Our findings indicate that influenza vaccination can induce protective antibody levels in a substantial proportion of heart transplant recipients and lend support to the recommendation to vaccinate such patients annually against influenza.

MeSH terms

  • Antibodies, Viral / analysis*
  • Female
  • Heart Transplantation*
  • Hemagglutination Inhibition Tests
  • Humans
  • Influenza A virus / immunology
  • Influenza B virus / immunology
  • Influenza Vaccines / immunology
  • Influenza, Human / prevention & control*
  • Male
  • Middle Aged
  • Vaccination* / adverse effects

Substances

  • Antibodies, Viral
  • Influenza Vaccines